This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).
Patients ≥18 years old
Newly diagnosed RCC by biopsy (preferred) or radiologic evidence of growth on surveillance over two consecutive assessments (6-12 months)
Primary lesion >3 cm, or recurrent lesion following local ablative therapy
Medically inoperable or patient who refuses surgery following assessment by experienced urologist, and discussed in a multidisciplinary setting
Primary Lesion >20cm
Evidence of distant metastatic disease
Previous abdominal RT in vicinity of kidney preventing definitive SBRT
History of major radiosensitivity syndrome
Sunnybrook Health Sciences Centre
Lead sponsor
Juravinski Cancer Center
Collaborator
Health Sciences North
Collaborator
Grand River Regional Cancer Centre
Collaborator
British Columbia Cancer Agency
Collaborator
London Health Sciences Centre
Collaborator
Durham Regional Cancer Centre
Collaborator